Griseofulvin Brown & Burk Ir (Griseofulvin)

Griseofulvin Brown & Burk Ir is prescribed for fungal infections of the skin, hair, and nails caused by dermatophytes.

• Dermatophytosis of the body (tinea corporis)
• Scalp infection (tinea capitis)
• Groin infection (tinea cruris)
• Foot infection (tinea pedis)
• Nail infection (tinea unguium)
• Ringworm infections affecting other body sites

Treatment duration typically extends for several weeks to months, depending on the infection site and clinical response.

Side effects reported with oral griseofulvin vary in frequency and severity.

Common

• Headache – mild to moderate discomfort that may resolve without treatment.
• Nausea, vomiting or loss of appetite – gastrointestinal upset common during early therapy.
• Diarrhea or abdominal cramps – may be transient and improve with continued dosing.
• Skin rash, pruritus or mild photosensitivity – skin irritation that usually subsides.

Serious

• Elevated liver enzymes or hepatitis – indicates potential hepatic injury requiring monitoring.
• Severe allergic reaction, including anaphylaxis or angioedema – requires immediate medical attention.
• Blood dyscrasias such as neutropenia, thrombocytopenia or anemia – may manifest as fatigue, bruising or infection risk.

Before initiating Griseofulvin Brown & Burk Ir, certain precautions should be considered to ensure safe use.

• Assess liver function; avoid use in patients with active hepatic disease.
• Review pregnancy and lactation status; griseofulvin is generally contraindicated during pregnancy.
• Evaluate for known hypersensitivity to griseofulvin or other antifungal agents.
• Monitor complete blood count during prolonged therapy to detect hematologic effects.
• Advise patients to avoid excessive sunlight exposure due to potential photosensitivity.
• Consider drug interactions with oral contraceptives, as efficacy may be reduced.
• Use caution in patients with renal impairment; dosage adjustment may be required.

Griseofulvin can alter the metabolism of several medications; awareness of interactions helps prevent therapeutic failure or toxicity.

Avoid

• Combined use with warfarin – increased anticoagulant effect.
• Concurrent administration with oral contraceptives – reduced contraceptive efficacy.
• Co‑administration with cyclosporine – heightened nephrotoxicity risk.

Use with caution

• Antiepileptic drugs such as phenobarbital, phenytoin or carbamazepine – may decrease griseofulvin levels.
• Rifampin or other enzyme‑inducing antibiotics – may lower griseofulvin exposure.
• Statins (e.g., simvastatin) – monitor for enhanced muscle toxicity.